2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Adenocarcinoma in 53 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib resistance remains a major problem in the treatment of lung adenocarcinoma." | 7.83 | FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop. ( Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X, 2016) |
| "Gefitinib resistance remains a major problem in the treatment of lung adenocarcinoma." | 3.83 | FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop. ( Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X, 2016) |
| "The Barrett's adenocarcinoma cell line, SEG-1, was exposed to the conjugated bile salt, glycochenodeoxycholic acid (GCDA)." | 3.72 | Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. ( Anthony, T; Jaiswal, K; Lopez-Guzman, C; Nwariaku, F; Sarosi, GA; Tello, V, 2004) |
| "Human pancreatic adenocarcinoma cell lines PK1 and PK8 are resistant to the clinically relevant chemotherapy agent gemcitabine." | 3.70 | Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. ( Chow, S; Hedley, DW; Tsao, MS, 2000) |
| "Expression and activity of metastasis‑related metalloproteinases (MMPs) were analyzed by western blotting and gelatin zymography, respectively." | 1.43 | CHRNA7 inhibits cell invasion and metastasis of LoVo human colorectal cancer cells through PI3K/Akt signaling. ( Chen, W; Fei, R; Qian, J; Xiang, T; Yu, F, 2016) |
| "We treated 7 ovarian cancer cell lines with CDDP alone or with CDDP and either a PI3K inhibitor (LY294002), a MEK inhibitor (PD98059), or a MEK/ERK activator (phorbol 12-myristate 13-acetate [PMA]) and assessed cell viability, expression of MEK/ERK and PI3K/Akt, cell cycle distribution, and apoptosis." | 1.38 | Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. ( Harada, T; Itamochi, H; Kawaguchi, W; Kigawa, J; Kudoh, A; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K, 2012) |
| "We have previously demonstrated that in pancreatic cancer ErbB3 is the preferred dimerization partner of EGFR, ErbB3 protein expression level directly correlates with the anti-proliferative effect of erlotinib (an EGFR-specific tyrosine kinase inhibitor), and transient knockdown of ErbB3 expression results in acquired resistance to EGFR-targeted therapy." | 1.36 | ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. ( Arnoletti, JP; Frolov, A; Heslin, MJ; Howard, JH; Kossenkov, AV; Kulesza, P; Liles, JS; Tzeng, CW, 2010) |
| "Gastric cancer is the most common cancer in Japan and infection with Epstein-Barr virus (EBV) is responsible for about 10% of gastric cancers worldwide." | 1.35 | Epstein-Barr virus upregulates phosphorylated heat shock protein 27 kDa in carcinoma cells using the phosphoinositide 3-kinase/Akt pathway. ( Fujimoto, M; Fukagawa, Y; Imai, S; Iwakiri, D; Kuramitsu, Y; Nakamura, K; Nishikawa, J; Okamoto, T; Okita, K; Sakaida, I; Satake, M; Takada, K, 2008) |
| "We hypothesize that pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies." | 1.35 | Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. ( Dixon, J; Holcomb, B; Kennard, J; Mahomed, J; Matos, JM; Schmidt, CM; Sebolt-Leopold, J; Shanmugam, R; Yip-Schneider, MT, 2008) |
| "Necrosis was significantly reduced (P < 0." | 1.33 | MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro. ( Cunningham, C; Frankenberry, K; Jackson, BJ; McFadden, DW; Riggs, DR; Szwerc, MF; Vona-Davis, L, 2005) |
| "In 88 gastric cancer tissue samples, phosphorylated Akt and VEGF expression were analyzed immunohistochemically." | 1.33 | Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. ( Kobayashi, I; Kuroda, Y; Matsuda, Y; Semba, S; Yokozaki, H, 2006) |
| "In PK-45H pancreatic cancer cells, the growth-inhibitory and apoptosis-inducing effects of LY294002, a PI3K inhibitor, were detected in a concentration-dependent manner, followed by the reduction of phosphorylated Akt levels." | 1.32 | Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. ( Kimura, W; Moriya, T; Semba, S; Yamakawa, M, 2003) |
| "Pancreatic cancer is resistant to almost all cytotoxic drugs." | 1.32 | Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. ( Arlt, A; Fölsch, UR; Gehrz, A; Kruse, ML; Müerköster, S; Schäfer, H; Vorndamm, J, 2003) |
| "All the gastric cancer cell lines tested were susceptible to TRAIL to some extent, except for SNU-216 cell line, which was completely resistant." | 1.32 | Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. ( Chung, HY; Hur, GC; Jung, GA; Kim, WH; Lee, BL; Nam, SY; Seol, DW, 2003) |
| "Using LNCaP prostate cancer cells as an experimental paradigm of FAS-overexpressing PTEN-null cancer cells, we demonstrate that LY294002, an inhibitor of the PI3k pathway causes a dramatic decrease in FAS protein expression." | 1.31 | Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. ( De Schrijver, E; Heyns, W; Swinnen, JV; Van de Sande, T; Verhoeven, G, 2002) |
| "Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer known." | 1.31 | Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. ( Bao, LW; Merajver, SD; Miller, FR; Pan, Q; van Golen, KL; Wu, ZF, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.77) | 18.2507 |
| 2000's | 32 (60.38) | 29.6817 |
| 2010's | 15 (28.30) | 24.3611 |
| 2020's | 4 (7.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, BJ | 1 |
| Hwang, MK | 1 |
| Park, M | 1 |
| Lee, K | 1 |
| Kim, SH | 1 |
| Sun, Y | 1 |
| Zhang, Z | 3 |
| Xiang, F | 1 |
| Zhang, M | 2 |
| Chen, Q | 1 |
| Tang, L | 1 |
| Zhu, L | 1 |
| Liu, J | 1 |
| Meng, Z | 1 |
| Hu, J | 1 |
| Luo, X | 1 |
| Ni, Z | 1 |
| Wang, X | 1 |
| Miyazaki, K | 1 |
| Togo, S | 1 |
| Okamoto, R | 1 |
| Idiris, A | 1 |
| Kumagai, H | 1 |
| Miyagi, Y | 1 |
| Piao, L | 1 |
| Che, N | 1 |
| Li, H | 2 |
| Li, M | 1 |
| Feng, Y | 1 |
| Liu, X | 1 |
| Kim, S | 1 |
| Jin, Y | 1 |
| Xuan, Y | 1 |
| Xu, M | 1 |
| Wang, J | 1 |
| Cheng, Z | 1 |
| Wang, YL | 1 |
| Zhu, BJ | 1 |
| Qi, ZZ | 1 |
| Wang, HJ | 1 |
| Zhou, XD | 1 |
| Tan, N | 1 |
| Zheng, H | 1 |
| Huang, JJ | 1 |
| Yang, XR | 1 |
| Wu, XL | 1 |
| Zha, Y | 1 |
| Xu, Y | 1 |
| Jiang, Z | 1 |
| Sun, N | 1 |
| Xie, J | 1 |
| Li, T | 1 |
| Hou, Y | 1 |
| Wu, D | 1 |
| Ito, S | 1 |
| Igishi, T | 1 |
| Takata, M | 1 |
| Ueda, Y | 1 |
| Matsumoto, S | 1 |
| Kodani, M | 1 |
| Takeda, K | 1 |
| Izumi, H | 1 |
| Sakamoto, T | 1 |
| Yamaguchi, K | 1 |
| Makino, H | 1 |
| Touge, H | 1 |
| Chikumi, H | 1 |
| Shimizu, E | 1 |
| Sonoki, H | 1 |
| Sato, T | 1 |
| Endo, S | 3 |
| Matsunaga, T | 3 |
| Yamaguchi, M | 2 |
| Yamazaki, Y | 2 |
| Sugatani, J | 2 |
| Ikari, A | 3 |
| Xiang, T | 1 |
| Yu, F | 1 |
| Fei, R | 1 |
| Qian, J | 2 |
| Chen, W | 1 |
| Shimobaba, S | 1 |
| Taga, S | 2 |
| Akizuki, R | 2 |
| Hichino, A | 2 |
| Watanabe, R | 1 |
| Wang, Y | 1 |
| Zhang, W | 1 |
| Wen, L | 1 |
| Yang, H | 1 |
| Wen, M | 1 |
| Yun, Y | 1 |
| Zhao, L | 1 |
| Zhu, X | 1 |
| Tian, L | 1 |
| Luo, E | 1 |
| Li, Y | 1 |
| Liu, W | 1 |
| Wen, N | 1 |
| Okamoto, M | 1 |
| Fukagawa, Y | 1 |
| Nishikawa, J | 1 |
| Kuramitsu, Y | 1 |
| Iwakiri, D | 1 |
| Takada, K | 1 |
| Imai, S | 1 |
| Satake, M | 1 |
| Okamoto, T | 1 |
| Fujimoto, M | 1 |
| Okita, K | 1 |
| Nakamura, K | 1 |
| Sakaida, I | 1 |
| Fong, YC | 1 |
| Liu, SC | 1 |
| Huang, CY | 1 |
| Li, TM | 1 |
| Hsu, SF | 1 |
| Kao, ST | 1 |
| Tsai, FJ | 1 |
| Chen, WC | 1 |
| Chen, CY | 1 |
| Tang, CH | 1 |
| Zou, Y | 1 |
| Rahman, JS | 1 |
| Lu, B | 1 |
| Massion, PP | 1 |
| Zhang, Y | 2 |
| Qu, X | 1 |
| Hu, X | 1 |
| Yang, X | 1 |
| Hou, K | 1 |
| Teng, Y | 1 |
| Zhang, J | 1 |
| Sada, K | 1 |
| Liu, Y | 1 |
| Prawettongsopon, C | 1 |
| Asawakarn, S | 1 |
| Suthiphongchai, T | 1 |
| Harfouche, R | 1 |
| Basu, S | 1 |
| Soni, S | 1 |
| Hentschel, DM | 1 |
| Mashelkar, RA | 1 |
| Sengupta, S | 1 |
| Liles, JS | 1 |
| Arnoletti, JP | 1 |
| Tzeng, CW | 1 |
| Howard, JH | 1 |
| Kossenkov, AV | 1 |
| Kulesza, P | 1 |
| Heslin, MJ | 1 |
| Frolov, A | 1 |
| Magloire Ketcha Wanda, GJ | 1 |
| Njamen, D | 1 |
| Tagatsing, FM | 1 |
| Yankep, E | 1 |
| Vollmer, G | 1 |
| Reka, AK | 1 |
| Kuick, R | 1 |
| Kurapati, H | 1 |
| Standiford, TJ | 1 |
| Omenn, GS | 1 |
| Keshamouni, VG | 1 |
| Tilli, TM | 1 |
| Mello, KD | 1 |
| Ferreira, LB | 1 |
| Matos, AR | 1 |
| Accioly, MT | 1 |
| Faria, PA | 1 |
| Bellahcène, A | 1 |
| Castronovo, V | 1 |
| Gimba, ER | 1 |
| Nonaka, M | 1 |
| Itamochi, H | 1 |
| Kawaguchi, W | 1 |
| Kudoh, A | 1 |
| Sato, S | 2 |
| Uegaki, K | 1 |
| Naniwa, J | 1 |
| Shimada, M | 1 |
| Oishi, T | 1 |
| Terakawa, N | 1 |
| Kigawa, J | 1 |
| Harada, T | 1 |
| Kodama, Y | 1 |
| Baxter, RC | 1 |
| Martin, JL | 1 |
| Windham, TC | 1 |
| Parikh, NU | 1 |
| Siwak, DR | 1 |
| Summy, JM | 1 |
| McConkey, DJ | 1 |
| Kraker, AJ | 1 |
| Gallick, GE | 1 |
| Plymate, SR | 1 |
| Haugk, KH | 1 |
| Sprenger, CC | 1 |
| Nelson, PS | 1 |
| Tennant, MK | 1 |
| Oberley, LW | 1 |
| Zhong, W | 1 |
| Drivdahl, R | 1 |
| Oberley, TD | 1 |
| Semba, S | 2 |
| Moriya, T | 1 |
| Kimura, W | 1 |
| Yamakawa, M | 1 |
| Arlt, A | 1 |
| Gehrz, A | 1 |
| Müerköster, S | 1 |
| Vorndamm, J | 1 |
| Kruse, ML | 1 |
| Fölsch, UR | 1 |
| Schäfer, H | 1 |
| Xu, Q | 1 |
| Karouji, Y | 1 |
| Kobayashi, M | 2 |
| Ihara, S | 1 |
| Konishi, H | 1 |
| Fukui, Y | 1 |
| Nam, SY | 1 |
| Jung, GA | 1 |
| Hur, GC | 1 |
| Chung, HY | 1 |
| Kim, WH | 1 |
| Seol, DW | 1 |
| Lee, BL | 1 |
| Zhao, Y | 1 |
| You, H | 1 |
| Yang, Y | 1 |
| Wei, L | 1 |
| Zhang, X | 1 |
| Yao, L | 1 |
| Fan, D | 1 |
| Yu, Q | 1 |
| Jaiswal, K | 1 |
| Tello, V | 1 |
| Lopez-Guzman, C | 1 |
| Nwariaku, F | 1 |
| Anthony, T | 1 |
| Sarosi, GA | 1 |
| Yi, HK | 1 |
| Kim, SY | 1 |
| Hwang, PH | 1 |
| Kim, CY | 1 |
| Yang, DH | 1 |
| Oh, Y | 1 |
| Lee, DY | 1 |
| Vona-Davis, L | 1 |
| Frankenberry, K | 1 |
| Cunningham, C | 1 |
| Riggs, DR | 1 |
| Jackson, BJ | 1 |
| Szwerc, MF | 1 |
| McFadden, DW | 1 |
| Coltella, N | 1 |
| Rasola, A | 1 |
| Nano, E | 1 |
| Bardella, C | 1 |
| Fassetta, M | 1 |
| Filigheddu, N | 1 |
| Graziani, A | 1 |
| Comoglio, PM | 1 |
| Di Renzo, MF | 1 |
| Coffey, JC | 1 |
| Wang, JH | 1 |
| Bouchier-Hayes, D | 1 |
| Cotter, TG | 1 |
| Redmond, HP | 1 |
| Sarinella, F | 1 |
| Calistri, A | 1 |
| Sette, P | 1 |
| Palù, G | 1 |
| Parolin, C | 1 |
| Kobayashi, I | 1 |
| Matsuda, Y | 1 |
| Kuroda, Y | 1 |
| Yokozaki, H | 1 |
| Uemura, Y | 1 |
| Nakata, H | 1 |
| Kubota, T | 1 |
| Bandobashi, K | 1 |
| Saito, T | 1 |
| Taguchi, H | 1 |
| Fedier, A | 1 |
| Erdmann, R | 1 |
| Boulikas, T | 1 |
| Fink, D | 1 |
| Renner, O | 1 |
| Fominaya, J | 1 |
| Alonso, S | 1 |
| Blanco-Aparicio, C | 1 |
| Leal, JF | 1 |
| Carnero, A | 1 |
| Holcomb, B | 1 |
| Yip-Schneider, MT | 1 |
| Matos, JM | 1 |
| Dixon, J | 1 |
| Kennard, J | 1 |
| Mahomed, J | 1 |
| Shanmugam, R | 1 |
| Sebolt-Leopold, J | 1 |
| Schmidt, CM | 1 |
| Phillips, TM | 1 |
| Kim, K | 1 |
| Vlashi, E | 1 |
| McBride, WH | 1 |
| Pajonk, F | 1 |
| Pan, ZK | 1 |
| Christiansen, SC | 1 |
| Ptasznik, A | 1 |
| Zuraw, BL | 1 |
| Asslan, R | 1 |
| Pradines, A | 1 |
| Pratx, C | 1 |
| Allal, C | 1 |
| Favre, G | 1 |
| Le Gaillard, F | 1 |
| Petiot, A | 1 |
| Ogier-Denis, E | 1 |
| Blommaart, EF | 1 |
| Meijer, AJ | 1 |
| Codogno, P | 1 |
| Lobenhofer, EK | 1 |
| Huper, G | 1 |
| Iglehart, JD | 1 |
| Marks, JR | 1 |
| Tsao, MS | 1 |
| Chow, S | 1 |
| Hedley, DW | 1 |
| Venkateswarlu, S | 1 |
| Dawson, DM | 1 |
| St Clair, P | 1 |
| Gupta, A | 1 |
| Willson, JK | 1 |
| Brattain, MG | 1 |
| Van de Sande, T | 1 |
| De Schrijver, E | 1 |
| Heyns, W | 1 |
| Verhoeven, G | 1 |
| Swinnen, JV | 1 |
| van Golen, KL | 1 |
| Bao, LW | 1 |
| Pan, Q | 1 |
| Miller, FR | 1 |
| Wu, ZF | 1 |
| Merajver, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Adenocarcinoma
| Article | Year |
|---|---|
Effects of recombinant erythropoietin on breast cancer-initiating cells.
Topics: Adenocarcinoma; Amyloid Precursor Protein Secretases; Breast Neoplasms; Cell Adhesion; Cell Division | 2007 |
52 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Adenocarcinoma
| Article | Year |
|---|---|
Thiourea compound AW00178 sensitizes human H1299 lung carcinoma cells to TRAIL-mediated apoptosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Res | 2012 |
Decreasing Arl4c expression by inhibition of AKT signal in human lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; ADP-Ribosylation Factors; Blotting, Western; Cam | 2020 |
Collective cancer cell invasion in contact with fibroblasts through integrin-α5β1/fibronectin interaction in collagen matrix.
Topics: A549 Cells; Adenocarcinoma; Amides; Benzamides; Cancer-Associated Fibroblasts; Cell Adhesion; Cell L | 2020 |
SETD8 promotes stemness characteristics and is a potential prognostic biomarker of gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Chrom | 2020 |
AIM2 inhibits colorectal cancer cell proliferation and migration through suppression of Gli1.
Topics: Adenocarcinoma; Aged; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Color | 2020 |
Akt1 enhances CA916798 expression through mTOR pathway.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Blotting, Western; Cell Line, Tumor; Chromones; DNA P | 2013 |
[Effect of P13K/AKT signal pathway regulation on expression of XIAP and cIAP2 in ovarian cancer cells].
Topics: Adenocarcinoma; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Cell Proli | 2013 |
HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromones; Cisplatin; Do | 2014 |
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anthracyclines; Carcinoma, Non-Small-Cell Lung; Cell Line, T | 2014 |
Quercetin Decreases Claudin-2 Expression Mediated by Up-Regulation of microRNA miR-16 in Lung Adenocarcinoma A549 Cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; | 2015 |
CHRNA7 inhibits cell invasion and metastasis of LoVo human colorectal cancer cells through PI3K/Akt signaling.
Topics: Adenocarcinoma; alpha7 Nicotinic Acetylcholine Receptor; Cell Division; Cell Line, Tumor; Cell Movem | 2016 |
Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Anoikis; Cell Line, Tumor; Cell Membrane Permeability; Cell Movement; Cell Prolifera | 2016 |
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Feedb | 2016 |
Down-regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Azacitidine; Butyric Acid; Cell Proliferation; C | 2017 |
Epstein-Barr virus upregulates phosphorylated heat shock protein 27 kDa in carcinoma cells using the phosphoinositide 3-kinase/Akt pathway.
Topics: Adenocarcinoma; Amino Acid Sequence; Androstadienes; Arsenites; Cell Line, Tumor; Cell Transformatio | 2008 |
Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway.
Topics: Adenocarcinoma; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Movement; Chrom | 2009 |
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Cell | 2009 |
Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Antineoplastic Agents; Apoptosis; ATP B | 2009 |
Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
Topics: Adenocarcinoma; Androgens; Animals; Cell Movement; Chromones; Enzyme Inhibitors; Extracellular Signa | 2009 |
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cells, Cultured; | 2009 |
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Re | 2010 |
Regulation of CD1, Ki-67, PCNA mRNA expression, and Akt activation in estrogen-responsive human breast adenocarcinoma cell line, MCF-7 cells, by griffonianone C, an isoflavone derived from Millettia griffoniana.
Topics: Adenocarcinoma; Antigens, CD1; Breast; Breast Neoplasms; Cell Line, Tumor; Chromones; Enzyme Inhibit | 2011 |
Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Benzoquinones; Biomarkers, Tumor; Blotting, Wes | 2011 |
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromon | 2012 |
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chromones; Cisplatin; | 2012 |
Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line.
Topics: Adenocarcinoma; Apoptosis; Cell Division; Chromones; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; | 2002 |
Src activation regulates anoikis in human colon tumor cell lines.
Topics: Adenocarcinoma; Amino Acid Substitution; Anoikis; Apoptosis; bcl-X Protein; Caspase 3; Caspases; Cel | 2002 |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.
Topics: Adenocarcinoma; Animals; Apoptosis; beta-Galactosidase; Carrier Proteins; Cell Line, Transformed; Ce | 2003 |
Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Apoptosis; Carcinoma, Pancreatic Ductal; Carcinoma, | 2003 |
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Dose-Response | 2003 |
The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma.
Topics: Adenocarcinoma; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Signet Ring Cell; Cell Comm | 2003 |
Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers.
Topics: Adenocarcinoma; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Chrom | 2003 |
Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Annexin A5; Apoptosis; Blotting, Western; Carrier Proteins; Caspases; Cell Line, Tum | 2004 |
Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Caspases; Cell Division; Cell Line, Tumor; Chromones; | 2004 |
Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Gene | 2005 |
MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Butadienes; Cell Division; Cell Line, Tumor; Cell Surv | 2005 |
p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tu | 2006 |
The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Division; Chromones; Enzyme Inhibitors; | 2006 |
Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromones; Flavonoids; Gene Deletion; Genes, ras; Genetic Therapy; | 2006 |
Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma.
Topics: Adenocarcinoma; Animals; Antigens, CD34; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Hypox | 2006 |
Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.
Topics: Adenocarcinoma; Cell Death; Cell Line, Tumor; Chromones; Disease Progression; Enzyme Activation; Ext | 2006 |
Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Base Pair Mismatch; Car | 2006 |
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Chromones; Class I Phosphatidylinositol 3-Kinases; Enzym | 2007 |
Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Prol | 2008 |
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Topics: Adenocarcinoma; Androstadienes; Bradykinin; Cells, Cultured; Chromones; Enzyme Inhibitors; Epithelia | 1999 |
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Topics: Adenocarcinoma; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Chromones; Epidermal | 1999 |
Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells.
Topics: Adenocarcinoma; Androstadienes; Autophagy; Chromones; Colonic Neoplasms; Enzyme Inhibitors; Homeosta | 2000 |
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
Topics: Adenocarcinoma; Androstadienes; Breast Neoplasms; Butadienes; Chromones; Culture Media, Serum-Free; | 2000 |
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Topics: Adenocarcinoma; Androstadienes; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine | 2000 |
Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.
Topics: Adenocarcinoma; Apoptosis; Autocrine Communication; Cell Cycle; Chromones; Colonic Neoplasms; Cultur | 2002 |
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Topics: Adenocarcinoma; Chromones; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Male; Morpholines; Phosp | 2002 |
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.
Topics: Adenocarcinoma; ADP Ribose Transferases; Botulinum Toxins; Breast Neoplasms; Chromones; Endothelial | 2002 |